AEterna Zentaris Announces Positive Results For Phase 2 Study With LHRH-Receptor Targeted...
AEterna Zentaris Inc. (NASDAQ: AEZS; TSX: AEZ) (the "Company"), a global biopharmaceutical company focused on endocrine therapy and oncology, announced positive efficacy data from a Phase 2 study with its targeted cytotoxic...



